Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating IMU-838 (vidofludimus) for relapsing-remitting multiple sclerosis; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• IMU-838 (IMU-838)

Snippet

Sponsor: Immunic AG | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: ACTIVE_NOT_RECRUITING